3-iodobenzylguanidine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, N; Igarashi, N; Igawa, A; Inoue, H; Matsuki, A; Nozawa, T; Ohori, T; Sobajima, M; Suzuki, T | 1 |
1 other study(ies) available for 3-iodobenzylguanidine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress.
Topics: 3-Iodobenzylguanidine; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dinoprost; Fatty Acids, Monounsaturated; Fluvastatin; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Iodine Radioisotopes; Male; Myocardium; NADPH Oxidases; Oxidative Stress; Radionuclide Imaging; Rats; Rats, Wistar; RNA, Messenger; Sympathetic Nervous System; Triglycerides | 2010 |